NeurANO Bioscience

3:00 PM - 4:00 PM (PDT), Tuesday, June 14, 2022
NeurANO Bioscience is a pre-clinical neuroscience drug discovery company developing first-in-class nanotherapeutics that are expected to be beneficial for the treatment of a wide range of neurological disorders, including Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, traumatic brain injury, depression, opioid addiction, and pain.
NeurANO’s core technology: Using FDA-approved components, we rationally designed novel nanotherapeutics to exclusively target extrasynaptic, but not synaptic, NMDA-type glutamatergic receptors. Such design makes our nanotherapeutics pathology-specific drugs without dangerous side effects accompanying broad-action antagonists of NMDA receptors. NeurANO was granted patents by the European Patent Office and Japanese Patent Office, and patent applications are pending at the USPTO and CNIPA.
Funding: NeurANO was awarded ~$1.4 M in grants from several NIH institutes, including the National Institute on Drug Abuse, the National Institute of Neurological Disorders and Stroke, and the National Institute on Aging.
By engaging in academic collaborations with world-class neuroscientists, NeurANO demonstrated strong therapeutic potential of our nanotherapeutics in such disease models as Huntington’s, Alzheimer’s, traumatic brain injury, pain, and opioid use disorder.
Speaker
photo
CEO
NeurANO Bioscience